September 27, 2011
Novartis AG announced new PIII data for its once-daily inhaled therapy NVA237 (glycopyrronium bromide) at Annual Congress 2011 of the European Respiratory Society (ERS) on September 27. In two studies, NVA237 significantly increased patients’ lung function compared to placebo with...read more